Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
Total Valuation
Autolus Therapeutics has a market cap or net worth of $364.61M. The enterprise value is $390.08M.
Market Cap$364.61M
Enterprise Value$390.08M
Share Statistics
Autolus Therapeutics has 266,143,280 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding266,143,280
Owned by Insiders―
Owned by Institutions32.83%
Financial Efficiency
Autolus Therapeutics’s return on equity (ROE) is -0.52 and return on invested capital (ROIC) is -33.53%.
Return on Equity (ROE)-0.52
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-33.53%
Return on Capital Employed (ROCE)-0.33
Revenue Per Employee15.64K
Profits Per Employee-341.05K
Employee Count647
Asset Turnover0.01
Inventory Turnover2.75
Valuation Ratios
The current PE Ratio of Autolus Therapeutics is ―. Autolus Therapeutics’s PEG ratio is 0.10.
PE Ratio―
PS Ratio59.25
PB Ratio1.40
Price to Fair Value1.40
Price to FCF-2.49
Price to Operating Cash Flow-1.29
PEG Ratio0.10
Income Statement
In the last 12 months, Autolus Therapeutics had revenue of 10.12M and earned -220.66M in profits. Earnings per share was -0.87.
Revenue10.12M
Gross Profit-130.90M
Operating Income-241.43M
Pretax Income-219.13M
Net Income-220.66M
EBITDA-233.07M
Earnings Per Share (EPS)-0.87
Cash Flow
In the last 12 months, operating cash flow was -254.18M and capital expenditures -23.86M, giving a free cash flow of -278.04M billion.
Operating Cash Flow-254.18M
Free Cash Flow-278.04M
Free Cash Flow per Share-1.04
Dividends & Yields
Autolus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.29
52-Week Price Change-58.73%
50-Day Moving Average1.49
200-Day Moving Average1.75
Relative Strength Index (RSI)48.26
Average Volume (3m)3.28M
Important Dates
Autolus Therapeutics upcoming earnings date is Mar 10, 2026, Before Open (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 10, 2026
Ex-Dividend Date―
Financial Position
Autolus Therapeutics as a current ratio of 10.88, with Debt / Equity ratio of 18.63%
Current Ratio10.88
Quick Ratio10.81
Debt to Market Cap0.41
Net Debt to EBITDA-0.30
Interest Coverage Ratio-25.98
Taxes
In the past 12 months, Autolus Therapeutics has paid 1.53M in taxes.
Income Tax1.53M
Effective Tax Rate>-0.01
Enterprise Valuation
Autolus Therapeutics EV to EBITDA ratio is -2.87, with an EV/FCF ratio of -2.78.
EV to Sales66.15
EV to EBITDA-2.87
EV to Free Cash Flow-2.78
EV to Operating Cash Flow-3.25
Balance Sheet
Autolus Therapeutics has $367.41M in cash and marketable securities with $65.83M in debt, giving a net cash position of $301.58M billion.
Cash & Marketable Securities$367.41M
Total Debt$65.83M
Net Cash$301.58M
Net Cash Per Share$1.13
Tangible Book Value Per Share$1.63
Margins
Gross margin is -67.31%, with operating margin of -2385.63%, and net profit margin of -2180.45%.
Gross Margin-67.31%
Operating Margin-2385.63%
Pretax Margin-2165.36%
Net Profit Margin-2180.45%
EBITDA Margin-2303.09%
EBIT Margin-2379.34%
Analyst Forecast
The average price target for Autolus Therapeutics is $7.68, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.68
Price Target Upside460.58% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast407.86%
EPS Growth Forecast30.14%